Plastic Surgery Research Council
Members Only  |  Contact  |  PSRC on Facebook

Back to Annual Meeting Program


VAPOCOOLANT SPRAY AS AN AJDUNCT TO REDUCE PAIN IN COSMETIC FACIAL INJECTIONS: A PROSPECTIVE STUDY USING A RANDOMIZED SPLIT-FACE MODEL
Presenter: Shahrooz S Kelishadi, MD
Co-Authors: Tutela JP; Rao AJ; Medina DC; Brooks RM; Chowdhry S; Wilhelmi BJ
University of Louisville

Background: Minimally invasive cosmetic procedures are the most commonly performed aesthetic techniques by plastic surgeons. Patients are interested in a pain-free experience. Surgeons desire patient satisfaction and time-efficient utilization of office staff and resources. Clinical evidence exists for use of vapocoolant technology to reduce pain associated with IV cannulation in the pediatric population and in hemodialysis patients. Applying vapocoolant technology to facial rejuvenation is a novel approach to decrease pain associated with neurotoxin or filler injection.

Methods: A prospective randomized study was conducted testing 15 subjects receiving filler injections and another 15 patients receiving neurotoxin injections using a split-face model. The vapocoolant spray tested consisted of a 95/5 ratio of 1,1,1,3,3 Pentafluoropropane and 1,1,1,2 Tetrafluoroethane. Within each group, subjects received in random order either the injectable corresponding to their group alone as a control or the injectable used in conjunction with the vapocoolant spray. Therefore, each patient randomly received injection (filler or neurotoxin) alone versus injection (filler or neurotoxin) plus vapocoolant on an equivalent half of his or her face. An independent examiner recorded from each patient on a scale of 1-10 perceived pain for injection alone versus injection plus vapocoolant spray. Male and female English speaking/literate volunteers aged 22-65 whom were either naive to or had prior exposure to neurotoxin or filler injections were studied. Subjects enrolled in other clinical studies or having consumed any narcotic medications within 48 hours of participation were excluded.

Results: Vapocoolant spray at the time of cosmetic facial injections lead to a 59% decreased percent change in perceived pain score with neurotoxin injections (range 0-100% change) and 64% decreased percent change in perceived pain score with filler injections (range 0-100% change). These results were statistically significant. See attached histograms.

Conclusion: Vapocoolant spray reduces pain associated with facial rejuvenation procedu


Back to Annual Meeting Program